Yunhyujeong 1 mg (Varenicline Salicylate)

Adult dose

After dose titration over 1 week, administer 1 mg twice daily. Days 1 – 3: 0.5 mg once daily Days 4 – 7: 0.5 mg twice daily Day 8 – end of treatment: 1 mg twice daily For patients who cannot tolerate the adverse reactions of this medicine, the dose may be reduced temporarily or permanently. The treatment period is 12 weeks. For patients who successfully quit smoking after the first 12 weeks of treatment, an additional 12 weeks of treatment with this medicine is recommended to increase the likelihood of long-term abstinence. Reduce smoking by 50% compared with baseline within the first 4 weeks after starting treatment, and by an additional 50% over the next 4 weeks. Continue to reduce smoking so that complete cessation is achieved by week 12. Continue this medicine for an additional 12 weeks for a total treatment period of 24 weeks. No dose adjustment is required in patients with mild (estimated creatinine clearance > 50 ml/min and ≤ 80 ml/min) to moderate (estimated creatinine clearance ≥ 30 ml/min and ≤ 50 ml/min) renal impairment. In patients with severe renal impairment (estimated creatinine clearance < 30 ml/min), the recommended starting dose of varenicline is 0.5 mg once daily. If needed, the maximum dose is 0.5 mg twice daily. In patients with end-stage renal disease receiving hemodialysis, if well tolerated, a maximum dose of 0.5 mg once daily may be administered. No dose adjustment is required in patients with hepatic impairment. Because renal function is more likely to be reduced in older adults, use caution when selecting the dose; monitoring renal function may be useful.

Child dose

Administration to patients under 18 years of age is not recommended.

This medication is used to assist in quitting smoking, and caution should be taken regarding neuropsychiatric symptoms and suicidal tendencies. Mental symptoms such as depression, anxiety, hallucinations, and aggression may occur during or after treatment. If such symptoms appear, stop taking the medication immediately and consult a doctor. Patients allergic to this medication or its components should not use it. Caution should also be exercised when administering this medication to pregnant or breastfeeding individuals, considering the effects on the fetus or baby. Discomfort, insomnia, and anxiety that may occur during smoking cessation could overlap with the side effects of this medication, requiring careful attention. The most common side effect is nausea, which can be alleviated by dose adjustment. Caution is advised during driving or operating machinery as drowsiness or decreased concentration may occur. Patients with underlying mental disorders or a history of seizures should consult a physician before taking this medication, and should stop taking it immediately if seizures occur. Patients with cardiovascular diseases should carefully assess the risks and benefits of using this medication, and inform a physician immediately of any heart-related symptoms. This medication does not have significant interactions with other drugs; however, behavioral changes may occur with alcohol consumption, so it is advisable to avoid or minimize alcohol intake during treatment. The safety and efficacy have not been established for children under the age of 18, and its use is not recommended. Elderly patients may require dose adjustments and renal function monitoring due to the potential for decreased kidney function. In the event of overdose, standard treatment procedures should be followed and dialysis may be considered if necessary. This medication should be stored out of reach of children and kept in its original container to maintain quality.

• Suicidal thoughts
• suicidal behavior
• suicide
• changes in behavior or thinking
• depression
• mania
• mood changes
• psychosis
• aggressive behavior
• hallucinations

This medication may be sensitive to air or moisture; therefore, it must be stored in a tightly sealed container. To maintain its efficacy, it is advisable to store it at room temperature, between 1 and 30 degrees Celsius.

Appearance

Light blue, bilaterally convex, rectangular film-coated tablets

Package unit

28 tablets (14 tablets/Blister X 2)